{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-155116","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2024-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.292622+00:00","generated_at":"2026-06-01T06:16:40.563413+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cogent Biosciences shareholders approve doubling authorized common stock to 300M shares","bullets":["Amendment increases authorized common shares from 150M to 300M; total authorized shares from 160M to 310M.","Outdated reverse stock split provisions deleted from the certificate of incorporation.","All three director nominees elected; Andrew Robbins received 67.8M for, Peter Harwin received 51.7M for.","Advisory vote on executive compensation passed with 69.6M for vs 6.7M against; future votes set for annual frequency."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-155116","json":"https://secwatch.observer/filing/0001193125-24-155116.json","markdown":"https://secwatch.observer/filing/0001193125-24-155116.md","text":"https://secwatch.observer/filing/0001193125-24-155116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312524155116/0001193125-24-155116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312524155116/d805683d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:16:40.563413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}